Trial Profile
Comparison of pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2011
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 02 Aug 2011 New trial record
- 23 Jul 2011 Results reported in an abstract at 23rd Congress of the International Society on Thrombosis and Haemostasis.